Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

The long non-coding RNA WT1-AS controls differentiation programs and leukemic cell fate in AML

View Full Paper
Ask AI
Bookmark
Share

Authors

PFPascal FichtelSBSilke Brilloff

Discussion

Loading...

Member takes

Overview

Knockdown of WT1-AS in AML cells demonstrates reduced leukemic stem cells and induces apoptosis, suggesting therapeutic potential.

Key Points

  • This research aims to explore the role of WT1-AS in regulating leukemic stem cell properties and differentiation in acute myeloid leukemia (AML).
  • Utilized shRNA-based knockdown to assess WT1-AS function in AML cell lines.
  • Conducted growth competition assays to evaluate the impact of WT1-AS knockdown on cell growth.
  • Analyzed apoptosis and cell cycle properties post-WT1-AS knockdown using transcriptomic analyses.
  • Performed in vivo competition assays using AML patient-derived xenografts with WT1-AS knockdown.
  • WT1-AS knockdown cells showed a significant growth disadvantage and increased apoptosis.
  • Observed cell cycle arrest at the G0/G1 phase in WT1-AS knockdown cells.
  • In vivo studies demonstrated a decrease in leukemic stem cells with WT1-AS knockdown, affirming its role as a tumor suppressor.
  • Higher WT1-AS expression associated with more aggressive leukemic stem cell profiles.

Cite This Study

Fichtel et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0dehttps://doi.org/10.1182/blood-2025-5022
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Low levels of wilms tumor 1 (WT1) protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia2025
  2. 2SMARCC1 loss impairs differentiation and enhances self-renewal in ASXL1-mutant hematopoietic cells2025
  3. 3Clone-specific epigenetic regulatory mechanisms in ASXL1-mutant chronic myelomonocytic leukemia2025
  4. 4Pre-malignant extracellular matrix drives leukemia transformation through reprogramming of pre-leukemic stem cells2025
  5. 5Targeting leukemic stem cell biomechanics suppresses stemness and enhances NK cell-mediated immunotherapy2025 · 2 citations